Glooko is excited to share that our digital health platform for people with diabetes and related chronic conditions is compatible in the United States with Insulet Corporation’s Omnipod® 5 Automated Insulin Delivery (AID) System.
The automated insulin delivery system, which is composed of the Omnipod 5 App, the Pod and has Dexcom® G6 Continuous Glucose Monitor (CGM) System integration, received FDA clearance for use by individuals ages 2 and older with type 1 diabetes in 2022.
As the first tubeless AID system with smartphone control* in the U.S., Omnipod 5 integrates with the Dexcom G6 CGM System to automatically adjust insulin, help protect against highs and lows in glucose levels**, and simplify life for people with diabetes. The system’s innovative Pod uses SmartAdjust™ technology that continuously and automatically regulates insulin delivery based on a patient’s customized Target Glucose.
“With the many benefits provided by the Omnipod 5, we’re thrilled it’s compatible and available to Glooko users in the U.S.,” said David Conn, Glooko’s Executive Vice President of Partnerships and Alliances. “Our partnership with Insulet allowed us to be compatible from launch with this innovative new AID system designed for people looking to better manage their diabetes.”
Through our integration with Insulet, patients using the Omnipod 5 can connect their system to Glooko and upload their data from home via a cloud connection, expediting the time spent with healthcare providers. Healthcare providers can review the data uploaded and view standardized, comprehensive reports in the Glooko dashboard to help gain insights and make decisions to optimize care.
“The team at Insulet appreciates the support Glooko provided to make the launch of the Omnipod 5 possible and successful,” said Dr. Trang Ly, MBBS, FRACP, Ph.D., Senior Vice President and Medical Director, Insulet. “This System has been life-changing for so many people living with type I diabetes and we look forward to continuing to see its impact.”
Along with the Omnipod 5, the Glooko platform is also compatible with Insulet Corporation’s Omnipod DASH®.
At Glooko, we’re continuously increasing the number of devices that are compatible with our digital health platform, and over 3 million users around the globe have benefited in managing their health with our tools. We’re currently compatible with a majority of global diabetes and health monitoring devices on the market, which gives patients and their healthcare providers flexibility in managing their diabetes and related chronic conditions.
*For a list of compatible smartphone devices visit omnipod.com/compatibility
**Study in 240 people with T1D aged 6 – 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-mo Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021).
Study in 80 people with T1D aged 2 – 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (12AM -< 6AM) from CGM in standard therapy vs. Omnipod 5 = 58.2% vs 81.0%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Median time with low blood glucose from CGM: standard therapy = 3.43% vs. 2.46%. Sherr JL, et al. Diabetes Care (2022).
MKT-0358 01
